海正药业(600267.SH)快速拉升 与圣兆药物扩大原料药合作
格隆汇4月24日丨海正药业(600267.SH)午后出现直线拉升走势,目前涨5.05%报17.69元,暂成交12.3亿元,最新总市值172亿元。圣兆药物21日发公告称,与海正药业签署重大合同,圣兆药物委托海正药业开发阿立哌唑(一水合物)无菌原料药的生产工艺,双方在圣兆药物指定的原料药受托生产企业共同完成阿立哌唑(一水合物)无菌原料药工艺验证批的生产。这是圣兆药物与海正药业达成的第2个原料药合作,均为精神神经领域产品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.